U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and ...

In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

These growth stocks come from completely different industries, but each has something to offer long-term investors.

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

The tech trade is proving resilient, even unstoppable, while the firms that gained by helping people lose weight are ...

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers. Download the app ...

I’ve had a very eventful year. At the beginning of 2025, my long-term relationship ended, and after a few months, I decided ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

The Milwaukee Bucks Health and Wellness program is celebrating its one-year anniversary. The free medical program was ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...

The post, at the company that focuses on care for GLP-1 users, comes after Yaccarino left Elon Musk's X in July.